{"id":810,"date":"2025-11-18T17:58:05","date_gmt":"2025-11-18T18:58:05","guid":{"rendered":"http:\/\/www.margatelm.com\/?p=810"},"modified":"2025-11-21T13:12:28","modified_gmt":"2025-11-21T13:12:28","slug":"access-uncertain-for-new-injectable-prep-as-the-affordable-care-acts-aca-open-enrollment-begins","status":"publish","type":"post","link":"http:\/\/www.margatelm.com\/index.php\/2025\/11\/18\/access-uncertain-for-new-injectable-prep-as-the-affordable-care-acts-aca-open-enrollment-begins\/","title":{"rendered":"Access Uncertain for New Injectable PrEP as the Affordable Care Act\u2019s (ACA) Open Enrollment Begins"},"content":{"rendered":"
This analysis examines access to, and consumers ability to find information on, a new twice annual long-acting PrEP drug during the first ACA open enrollment period since its approval. Despite the drug widely being considered a major advance, early evidence suggests that insurance coverage and benefit design decisions may create barriers to access.<\/p>\n","protected":false},"excerpt":{"rendered":"